Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF).

Rbm20-ASO treatment normalized several parameters, including LV chamber stiffness (EDPVR(β); Figure 3 D ), and LVEDP ( Figure 3 F ), with a decreasing trend observed in the relaxation time constant ( Figure 3 E ), which normalized the time constant of 2-hit-ASO to the level observed in control mice.

also in 47,180 other papers